188 related articles for article (PubMed ID: 31138773)
1. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p.
Bai F; Yu Z; Gao X; Gong J; Fan L; Liu F
Aging (Albany NY); 2019 May; 11(10):3198-3219. PubMed ID: 31138773
[TBL] [Abstract][Full Text] [Related]
2. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study.
Zambrano T; Hirata RDC; Hirata MH; Cerda Á; Salazar LA
Eur J Pharm Sci; 2018 May; 117():55-61. PubMed ID: 29427701
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
4. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
O'Grady S; Crown J; Duffy MJ
Med Oncol; 2022 Jul; 39(10):142. PubMed ID: 35834073
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of Simvastatin in Human Breast Cancer MCF-7 and MDA-MB-231 Cell Lines.
Rezano A; Ridhayanti F; Rangkuti AR; Gunawan T; Winarno GNA; Wijaya I
Asian Pac J Cancer Prev; 2021 Feb; 22(S1):33-42. PubMed ID: 33576210
[TBL] [Abstract][Full Text] [Related]
6. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
Wolfe AR; Debeb BG; Lacerda L; Larson R; Bambhroliya A; Huang X; Bertucci F; Finetti P; Birnbaum D; Van Laere S; Diagaradjan P; Ruffell B; Trenton NJ; Chu K; Hittelman W; Diehl M; Levental I; Ueno NT; Woodward WA
Breast Cancer Res Treat; 2015 Dec; 154(3):495-508. PubMed ID: 26590814
[TBL] [Abstract][Full Text] [Related]
8. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
[TBL] [Abstract][Full Text] [Related]
9. A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer.
Sun Q; Arnold RS; Sun CQ; Petros JA
Prostate; 2015 Dec; 75(16):1916-25. PubMed ID: 26383260
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin is effective in killing the radioresistant breast carcinoma cells.
Aschenbrenner B; Negro G; Savic D; Sorokin M; Buzdin A; Ganswindt U; Cemazar M; Sersa G; Skvortsov S; Skvortsova I
Radiol Oncol; 2021 May; 55(3):305-316. PubMed ID: 33939900
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin inhibits the proliferation of A549 lung cancer cells through oxidative stress and up-regulation of SOD2.
Li Y; Fu J; Yuan X; Hu C
Pharmazie; 2014 Aug; 69(8):610-4. PubMed ID: 25158572
[TBL] [Abstract][Full Text] [Related]
12. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells.
Alizadeh J; Zeki AA; Mirzaei N; Tewary S; Rezaei Moghadam A; Glogowska A; Nagakannan P; Eftekharpour E; Wiechec E; Gordon JW; Xu FY; Field JT; Yoneda KY; Kenyon NJ; Hashemi M; Hatch GM; Hombach-Klonisch S; Klonisch T; Ghavami S
Sci Rep; 2017 Mar; 7():44841. PubMed ID: 28344327
[TBL] [Abstract][Full Text] [Related]
13. Integration of Ca
Abdoul-Azize S; Buquet C; Li H; Picquenot JM; Vannier JP
Oncogene; 2018 Sep; 37(36):4979-4993. PubMed ID: 29795329
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells.
Zhao Z; Cao X; Pan Y; Sha S; Zhao T; Zhang T
Oncol Res; 2012; 20(5-6):187-95. PubMed ID: 23581225
[TBL] [Abstract][Full Text] [Related]
15. The potential use of simvastatin for cancer treatment: A review.
Duarte JA; de Barros ALB; Leite EA
Biomed Pharmacother; 2021 Sep; 141():111858. PubMed ID: 34323700
[TBL] [Abstract][Full Text] [Related]
16. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells.
Dewidar SA; Hamdy O; Soliman MM; El Gayar AM; El-Mesery M
Med Oncol; 2023 Dec; 41(1):7. PubMed ID: 38051378
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK.
Koyuturk M; Ersoz M; Altiok N
Cancer Lett; 2007 Jun; 250(2):220-8. PubMed ID: 17125918
[TBL] [Abstract][Full Text] [Related]
18. Effect of simvastatin on castration-resistant prostate cancer cells.
Kim JH; Cox ME; Wasan KM
Lipids Health Dis; 2014 Mar; 13():56. PubMed ID: 24666612
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
Aberg M; Wickström M; Siegbahn A
Thromb Res; 2008; 122(2):191-202. PubMed ID: 18031796
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers.
Matusewicz L; Filip-Psurska B; Psurski M; Tabaczar S; Podkalicka J; Wietrzyk J; Ziółkowski P; Czogalla A; Sikorski AF
Int J Pharm; 2019 Oct; 569():118605. PubMed ID: 31400433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
